BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Isatuximab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Isatuximab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06517017-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Isatuximab: Phase 2 readout est. (NCT06517017)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Use of Isatuxi
 mab\, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail 
 Patients With Multiple Myeloma\nEstimated primary completion: November 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06517017
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03989414-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Isatuximab: Phase 1/2 readout est. (NCT03989414)
DESCRIPTION:Isatuximab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to D
 etermine the Recommended Dose and Regimen and to Evaluate the Safety and P
 reliminary Efficacy of CC-92480 in Combination With Standard Treatments in
  Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newl
 y Diagnosed Multiple Myeloma (NDMM)\nEstimated primary completion: 30 Nove
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT039
 89414
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06832865-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Isatuximab: Phase 2 readout est. (NCT06832865)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: ELISA in Relap
 sed/Refractory MM\nEstimated primary completion: 1 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06832865
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04883242-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Isatuximab: Phase 2 readout est. (NCT04883242)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\, C
 arfilzomib\, Pomalidomide\, and Dexamethasone for the Treatment of Relapse
 d or Refractory Multiple Myeloma\nEstimated primary completion: 31 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT048832
 42
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05558319-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Isatuximab: Phase 3 readout est. (NCT05558319)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: NDMM Patients 
 Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iber
 domide\nEstimated primary completion: April 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05558319
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04835129-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Isatuximab: Phase 2 readout est. (NCT04835129)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\, P
 omalidomide\, Elotuzumab and Dexamethasone in Relapsed and/or Refractory M
 ultiple Myeloma\nEstimated primary completion: 1 April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04835129
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356571-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Isatuximab: Phase 2 readout est. (NCT06356571)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: A Study to Inv
 estigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib an
 d Dexamethasone in Adult Participants With Relapsed and/or Refractory Mult
 iple Myeloma\nEstimated primary completion: 1 April 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06356571
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03319667-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:Isatuximab: Phase 3 readout est. (NCT03319667)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: A Study to Inv
 estigate the Clinical Benefit of Isatuximab in Combination With Bortezomib
 \, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple 
 Myeloma Not Eligible for Transplant\nEstimated primary completion: 5 April
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0331966
 7
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02960555-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Isatuximab: Phase 2 readout est. (NCT02960555)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab Wit
 h or Without Lenalidomide in Patients With High Risk Smoldering Multiple M
 yeloma (ISAMAR)\nEstimated primary completion: 30 April 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT02960555
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04754945-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270506
DTEND;VALUE=DATE:20270507
SUMMARY:Isatuximab: Phase 1 readout est. (NCT04754945)
DESCRIPTION:Isatuximab\, phase 1.\nStudy: Isatuximab as Upfront Therapy for
  the Treatment of High Risk AL Amyloidosis\nEstimated primary completion: 
 6 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/isatuxima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 754945
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05873205-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270629
DTEND;VALUE=DATE:20270630
SUMMARY:Isatuximab: Phase 2 readout est. (NCT05873205)
DESCRIPTION:Isatuximab\, phase 2.\nStudy: Open-Label\, Phase II Trial of Is
 atuximab for Patients With Refractory Immune Cytopenias After Allogeneic H
 ematopoietic Cell Transplantation\nEstimated primary completion: 29 June 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05873205
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07479979-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Isatuximab: Phase 1/2 readout est. (NCT07479979)
DESCRIPTION:Isatuximab\, phase 1/2\, Multiple Myeloma.\nStudy: Study of Sel
 inexor With Carfilzomib\, Isatuximab and Dexamethasone for Patients With R
 elapsed and/or Refractory Multiple Myeloma\nEstimated primary completion: 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 79979
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05346809-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Isatuximab: Phase 2 readout est. (NCT05346809)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab Dur
 ing Stem Cell Collection and Transplant in Patients With Multiple Myeloma 
 and Lymphoma\nEstimated primary completion: July 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05346809
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05665140-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Isatuximab: Phase 2/3 readout est. (NCT05665140)
DESCRIPTION:Isatuximab\, phase 2/3\, Multiple Myeloma.\nStudy: Expression-l
 inked and R-ISS-adapted Stratification for First Line Therapy in Multiple 
 Myeloma Patients\nEstimated primary completion: August 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05665140
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04643002-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Isatuximab: Phase 1/2 readout est. (NCT04643002)
DESCRIPTION:Isatuximab\, phase 1/2\, Multiple Myeloma.\nStudy: Isatuximab i
 n Combination With Novel Agents in RRMM - Master Protocol\nEstimated prima
 ry completion: 13 September 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/isatuximab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04643002
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789522-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20271009
DTEND;VALUE=DATE:20271010
SUMMARY:Isatuximab: Phase 2 readout est. (NCT07789522)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Safety and Eff
 icacy of Elranatamab Plus Isatuximab\, Bortezomib\, and Lenalidomide in Ul
 tra-High-Risk Multiple Myeloma\nEstimated primary completion: 9 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07789522
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828522-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20271009
DTEND;VALUE=DATE:20271010
SUMMARY:Isatuximab: Phase 2 readout est. (NCT07828522)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: F182112 in Com
 bination With Isatuximab and Lenalidomide for the Treatment of Patients Wi
 th Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 9 Octob
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07828
 522
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04850599-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Isatuximab: Phase 2 readout est. (NCT04850599)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\, C
 arfilzomib\, and Pomalidomide for the Treatment of Relapsed or Refractory 
 Multiple Myeloma\nEstimated primary completion: 15 October 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04850599
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04891809-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Isatuximab: Phase 2 readout est. (NCT04891809)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab in 
 Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) 
 With NDMM\nEstimated primary completion: December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04891809
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04558931-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Isatuximab: Phase 2 readout est. (NCT04558931)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Clinical Trial
  for Autologus NK Cells Alone or in Combination With Isatuximab as Mainten
 ance for Multiple Myeloma\nEstimated primary completion: 31 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04558931
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05776979-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Isatuximab: Phase 2 readout est. (NCT05776979)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Post-Transplan
 t Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Mult
 iple Myeloma Patients\nEstimated primary completion: 31 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05776979
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05272826-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Isatuximab: Phase 2 readout est. (NCT05272826)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Study of Iberd
 omide\, Bortezomib\, Dexamethasone With Isatuximab Added on Demand for ND-
 NTE MM Patients\nEstimated primary completion: March 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05272826
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05137054-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280325
DTEND;VALUE=DATE:20280326
SUMMARY:Isatuximab: Phase 1 readout est. (NCT05137054)
DESCRIPTION:Isatuximab\, phase 1\, Multiple Myeloma.\nStudy: A Study to Exa
 mine the Effects of Novel Therapy Linvoseltamab in Combination With Other 
 Cancer Treatments for Adult Participants With Multiple Myeloma That is Res
 istant to Current Standard of Care Treatments\nEstimated primary completio
 n: 25 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/isa
 tuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05137054
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07045909-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Isatuximab: Phase 2 readout est. (NCT07045909)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Efficacy and S
 afety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Mu
 ltiple Myeloma (GEM-AnitoFIRST)\nEstimated primary completion: 31 March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07045909
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07585760-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Isatuximab: Phase 2 readout est. (NCT07585760)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: CM336 Plus Isa
 tuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment\nEstima
 ted primary completion: 1 May 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/isatuximab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07585760
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03617731-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Isatuximab: Phase 3 readout est. (NCT03617731)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: Trial on the E
 ffect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Inducti
 on and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (
 GMMG HD7)\nEstimated primary completion: June 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03617731
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07714512-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Isatuximab: Phase 1/2 readout est. (NCT07714512)
DESCRIPTION:Isatuximab\, phase 1/2.\nStudy: Phase I/II Study of Anti-CD38 M
 onoclonal Antibody in Refractory Severe Aplastic Anemia\nEstimated primary
  completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/isatuximab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07714512
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07334535-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Isatuximab: Phase 4 readout est. (NCT07334535)
DESCRIPTION:Isatuximab\, phase 4\, Multiple Myeloma.\nStudy: Isa-VRD in TIE
  HRMM\nEstimated primary completion: July 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07334535
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05669989-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Isatuximab: Phase 2 readout est. (NCT05669989)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: International 
 Treatment-extension Study in Adult Participants With Multiple Myeloma and 
 Who Have Derived Clinical Benefit From Isatuximab\nEstimated primary compl
 etion: 30 November 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/isatuximab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05669989
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04786028-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Isatuximab: Phase 2 readout est. (NCT04786028)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Isa
 tuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Tr
 eatments in ND-TEMM\nEstimated primary completion: December 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04786028
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06216158-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Isatuximab: Phase 3 readout est. (NCT06216158)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: Iberdomide vs.
  Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnos
 ed Multiple Myeloma\nEstimated primary completion: December 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06216158
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05922501-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Isatuximab: Phase 2 readout est. (NCT05922501)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\, B
 ela Maf\, Pom\, and Dex in Relapsed/Refractory Multiple Myeloma\nEstimated
  primary completion: 31 December 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/isatuximab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05922501
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07732712-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Isatuximab: Phase 2/3 readout est. (NCT07732712)
DESCRIPTION:Isatuximab\, phase 2/3\, Multiple Myeloma.\nStudy: Isa-VRdlite 
 for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Mul
 tiple Myeloma Base on Circulating Plasma Cells\nEstimated primary completi
 on: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /isatuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07732712
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764978-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:Isatuximab: Phase 3 readout est. (NCT07764978)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: Study of AZD01
 20 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT\nEstimated prim
 ary completion: 11 January 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/isatuximab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07764978
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06648889-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Isatuximab: Phase 2 readout est. (NCT06648889)
DESCRIPTION:Isatuximab\, phase 2.\nStudy: Isatuximab in Adult Patients With
  Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lym
 phoblastic Leukemia\nEstimated primary completion: June 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06648889
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07652905-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Isatuximab: Phase 2 readout est. (NCT07652905)
DESCRIPTION:Isatuximab\, phase 2.\nStudy: CM336 Plus Isa-VR in Newly Diagno
 sed Primary Plasma Cell Leukemia\nEstimated primary completion: 30 June 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07652905
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07601100-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Isatuximab: Phase 1/2 readout est. (NCT07601100)
DESCRIPTION:Isatuximab\, phase 1/2\, Multiple Myeloma.\nStudy: Isatuximab\,
  Iberdomide\, Bortezomib\, Dexamethasone in Transplant Ineligible/Deferred
  Newly Diagnosed Myeloma\nEstimated primary completion: 1 July 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07601100
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04240054-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Isatuximab: Phase 2 readout est. (NCT04240054)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Bortezomib\, I
 satuximab\, Cyclophosphamide and Dexamethasone Induction in Transplant-Eli
 gible Multiple Myeloma Patients With Renal Insufficiency\nEstimated primar
 y completion: 1 December 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/isatuximab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04240054
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903623-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Isatuximab: Phase 2 readout est. (NCT07903623)
DESCRIPTION:Isatuximab\, phase 2.\nStudy: QLS4131 Plus Isatuximab in Newly 
 Diagnosed Primary Plasma Cell Leukemia\nEstimated primary completion: 30 D
 ecember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/isatuxi
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07903623
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04270409-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20301014
DTEND;VALUE=DATE:20301015
SUMMARY:Isatuximab: Phase 3 readout est. (NCT04270409)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: Isatuximab in 
 Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Mu
 ltiple Myeloma\nEstimated primary completion: 14 October 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04270409
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05344833-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Isatuximab: Phase 2 readout est. (NCT05344833)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Post-Autologou
 s Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Resid
 ual Disease Positive Multiple Myeloma\nEstimated primary completion: Decem
 ber 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0534
 4833
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06762769-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20321101
DTEND;VALUE=DATE:20321102
SUMMARY:Isatuximab: Phase 2 readout est. (NCT06762769)
DESCRIPTION:Isatuximab\, phase 2.\nStudy: Isatuximab and Iberdomide as Immu
 notherapy for High Risk in Smouldering Myeloma\nEstimated primary completi
 on: 1 November 2032. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 isatuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06762769
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05145400-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20330528
DTEND;VALUE=DATE:20330529
SUMMARY:Isatuximab: Phase 2 readout est. (NCT05145400)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Isa-Rd for Fra
 il and/or Much Older Patients With Newly Diagnosed Multiple Myeloma\nEstim
 ated primary completion: 28 May 2033. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/isatuximab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05145400
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624513-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20331001
DTEND;VALUE=DATE:20331002
SUMMARY:Isatuximab: Phase 3 readout est. (NCT07624513)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: D2 - Isa-Iber-
 VD Induction\, Followed by Risk & Response Adapted Consolidation & Mainten
 ance\, in Transplant-Eligible NDMM\nEstimated primary completion: 1 Octobe
 r 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076245
 13
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06860269-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20350315
DTEND;VALUE=DATE:20350316
SUMMARY:Isatuximab: Phase 2/3 readout est. (NCT06860269)
DESCRIPTION:Isatuximab\, phase 2/3.\nStudy: A 3-cohort Randomized Study Eva
 luating the Role of New Immunotherapeutic Agents and of Allogeneic Hematop
 oietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults Wit
 h Acute Lymphoblastic Leukemia\nEstimated primary completion: 15 March 203
 5. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06860269
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07600151-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20360930
DTEND;VALUE=DATE:20361001
SUMMARY:Isatuximab: Phase 1/2 readout est. (NCT07600151)
DESCRIPTION:Isatuximab\, phase 1/2\, Multiple Myeloma.\nStudy: Etenta-Isa-V
 Rd in Newly Diagnosed High-Risk Multiple Myeloma\nEstimated primary comple
 tion: 30 September 2036. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/isatuximab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07600151
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903506-3136@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20390331
DTEND;VALUE=DATE:20390401
SUMMARY:Isatuximab: Phase 3 readout est. (NCT07903506)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: To Evaluate Sa
 fety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell
  Transplant in Newly Diagnosed Multiple Myeloma\nEstimated primary complet
 ion: March 2039. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/isat
 uximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07903506
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
